Device-based Therapy for Hypertension

Hypertension continues to be a major contributor to global morbidity and mortality, fuelled by an abundance of patients with uncontrolled blood pressure despite the multitude of pharmacological options available. This may occur as a consequence of true resistant hypertension, through an inability to tolerate current pharmacological therapies, or non-adherence to antihypertensive medication. In recent years, there has been a rapid expansion of device-based therapies proposed as novel non-pharmacological approaches to treating resistant hypertension. In this review, we discuss seven novel devices—renal nerve denervation, baroreflex activation therapy, carotid body ablation, central iliac arteriovenous anastomosis, deep brain stimulation, median nerve stimulation, and vagal nerve stimulation. We highlight how the devices differ, the varying degrees of evidence available to date and upcoming trials. This review also considers the possible factors that may enable appropriate device selection for different hypertension phenotypes.

[1]  R. Bandler,et al.  Viscerotopic organization of neurons subserving hypotensive reactions within the midbrain periaqueductal grey: a correlative functional and anatomical study , 1991, Brain Research.

[2]  G. Chatellier,et al.  Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. , 2015, European heart journal.

[3]  A. Stanton,et al.  Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial , 2015, The Lancet.

[4]  I. Dasgupta,et al.  Non-adherence to antihypertensive medication is very common among resistant hypertensives: results of a directly observed therapy clinic , 2016, Journal of Human Hypertension.

[5]  W. Elliott Resistant Hypertension: Diagnosis, Evaluation, and Treatment: A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research , 2009 .

[6]  P. Gosse,et al.  Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial , 2015, The Lancet.

[7]  Jens Jordan,et al.  Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. , 2010, Journal of the American College of Cardiology.

[8]  D. Paterson,et al.  Differentiated Baroreflex Modulation of Sympathetic Nerve Activity During Deep Brain Stimulation in Humans , 2014, Hypertension.

[9]  R. Victor Carotid baroreflex activation therapy for resistant hypertension , 2015, Nature Reviews Cardiology.

[10]  J. Nährig,et al.  Morphological assessment of renal arteries after radiofrequency catheter-based sympathetic denervation in a porcine model , 2012, Journal of hypertension.

[11]  T. Lovick Ventrolateral medullary lesions block the antinociceptive and cardiovascular responses elicited by stimulating the dorsal periaqueductal grey matter in rats , 1985, Pain.

[12]  A. Fletcher,et al.  Discontinuation of and changes in treatment after start of new courses of antihypertensive drugs: a study of a United Kingdom population , 1995, BMJ.

[13]  G. Bakris,et al.  Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. , 2012, Journal of the American Society of Hypertension : JASH.

[14]  B. Whipp,et al.  Immediate effects of bilateral carotid body resection on total respiratory resistance and compliance in humans. , 2004, Advances in experimental medicine and biology.

[15]  J. Staessen,et al.  Blood pressure changes after renal denervation at 10 European expert centers , 2013, Journal of Human Hypertension.

[16]  Mortimer Gierthmuehlen,et al.  Effect of selective vagal nerve stimulation on blood pressure, heart rate and respiratory rate in rats under metoprolol medication , 2016, Hypertension Research.

[17]  Daniel W. Jones,et al.  A Scientific Statement From the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research , 2008 .

[18]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[19]  M. Böhm,et al.  Reduced Effect of Percutaneous Renal Denervation on Blood Pressure in Patients With Isolated Systolic Hypertension , 2015, Hypertension.

[20]  R. Wachter,et al.  Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. , 2012, Journal of the American Society of Hypertension : JASH.

[21]  H. Krum,et al.  Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial. , 2014, European heart journal.

[22]  M. Andrassy,et al.  Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry , 2014, Clinical Research in Cardiology.

[23]  J. Paton,et al.  Arteriovenous Anastomosis: Is This the Way to Control Hypertension? , 2014, Hypertension.

[24]  Brad S. Hubbard,et al.  A novel non-vascular system to treat resistant hypertension. , 2013, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[25]  Deepak L. Bhatt,et al.  Refining calcium test for diagnosis of medullary thyroid cancer: cutoffs, procedures and safety , 2014, The New England journal of medicine.

[26]  J F R Paton,et al.  Deep brain stimulation relieves refractory hypertension , 2011, Neurology.

[27]  E. Regar,et al.  Multimodality Intra-Arterial Imaging Assessment of the Vascular Trauma Induced by Balloon-Based and Nonballoon-Based Renal Denervation Systems , 2015, Circulation. Cardiovascular interventions.

[28]  Thomas Stieglitz,et al.  Blood pressure control with selective vagal nerve stimulation and minimal side effects , 2014, Journal of neural engineering.

[29]  F. Ikeno,et al.  Transcatheter Alcohol-Mediated Perivascular Renal Denervation With the Peregrine System: First-in-Human Experience. , 2016, JACC. Cardiovascular interventions.

[30]  Ajay K. Jain,et al.  The ROX coupler: Creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature , 2015, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[31]  Elena G Tolkacheva,et al.  Intermittent electrical stimulation of the right cervical vagus nerve in salt-sensitive hypertensive rats: effects on blood pressure, arrhythmias, and ventricular electrophysiology , 2015, Physiological reports.

[32]  C. Cooper,et al.  An arteriovenous fistula increases exercise capacity in patients with COPD. , 2010, Chest.

[33]  D. Paterson,et al.  Deep brain stimulation of the periaqueductal grey induces vasodilation in humans. , 2011, Hypertension.

[34]  A. Zanchetti,et al.  Functional role of renal afferents. , 1991, Physiological reviews.

[35]  M. Caulfield,et al.  Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension , 2014, Heart.

[36]  J. Staessen,et al.  Renal denervation in treatment-resistant hypertension: a reappraisal. , 2015, Current opinion in pharmacology.

[37]  W. Anderson,et al.  Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. , 1988, Hypertension.

[38]  J. Paton,et al.  The Carotid Body as a Therapeutic Target for the Treatment of Sympathetically Mediated Diseases , 2013, Hypertension.

[39]  Giuseppe Mancia,et al.  The Autonomic Nervous System and Hypertension , 2014, Circulation research.

[40]  R. Wachter,et al.  Baroreflex Activation Therapy for the Treatment of Heart Failure With a Reduced Ejection Fraction. , 2015, JACC. Heart failure.

[41]  R. Virmani,et al.  Renal denervation therapy for hypertension: pathways for moving development forward. , 2015, Journal of the American Society of Hypertension : JASH.

[42]  K. Kuck,et al.  Results of the ALSTER BP real-world registry on renal denervation employing the Symplicity system. , 2014, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[43]  A. Kroon,et al.  Bilateral or Unilateral Stimulation for Baroreflex Activation Therapy , 2015, Hypertension.

[44]  J P Gassler,et al.  Baroreflex activation therapy in hypertension , 2014, Journal of Human Hypertension.

[45]  A. Kroon,et al.  Effects of Chronic Baroreceptor Stimulation on the Autonomic Cardiovascular Regulation in Patients With Drug-Resistant Arterial Hypertension , 2009, Hypertension.

[46]  J. Longhurst,et al.  Long-Lasting Reduction of Blood Pressure by Electroacupuncture in Patients with Hypertension: Randomized Controlled Trial , 2015, Medical acupuncture.

[47]  T. Stieglitz,et al.  Haemodynamic Responses to Selective Vagal Nerve Stimulation under Enalapril Medication in Rats , 2016, PloS one.

[48]  Ajay K. Jain,et al.  Central arteriovenous anastomosis for hypertension: it is not all about sympathomodulation. , 2015, Future cardiology.

[49]  G. Bakris,et al.  Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. , 2011, Journal of the American College of Cardiology.

[50]  M. Esler,et al.  The sympathetic system and hypertension. , 2000, American journal of hypertension.

[51]  R. Wachter,et al.  Impact of Baroreflex Activation Therapy on Renal Function - A Pilot Study , 2014, American Journal of Nephrology.

[52]  T. Zelinka,et al.  Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis , 2013, Journal of hypertension.

[53]  R. Whitbourn,et al.  First Report of the Global SYMPLICITY Registry on the Effect of Renal Artery Denervation in Patients With Uncontrolled Hypertension , 2015, Hypertension.

[54]  K. Shipman A controlled trial of renal denervation for resistant hypertension , 2014 .

[55]  Deepak L. Bhatt,et al.  Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. , 2015, European heart journal.

[56]  M. Caulfield,et al.  Renal artery sympathetic denervation: observations from the UK experience , 2016, Clinical Research in Cardiology.

[57]  B. Geršak,et al.  Frequency dependent effect of selective biphasic left vagus nerve stimulation on heart rate and arterial pressure , 2012 .

[58]  J. Longhurst,et al.  Electroacupuncture modulation of reflex hypertension in rats: role of cholecystokinin octapeptide. , 2013, American journal of physiology. Regulatory, integrative and comparative physiology.

[59]  C. Di Mario,et al.  Renal denervation for the management of resistant hypertension , 2015, Integrated blood pressure control.

[60]  Ajay K. Jain,et al.  Renal Sympathetic Denervation - A Review of Applications in Current Practice. , 2013, Interventional cardiology.

[61]  T. Lüscher,et al.  Vascular lesions induced by renal nerve ablation as assessed by optical coherence tomography: pre- and post-procedural comparison with the Simplicity® catheter system and the EnligHTN™ multi-electrode renal denervation catheter , 2013, European heart journal.

[62]  Krzysztof Bartus,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2009, The Lancet.

[63]  E. Dolan,et al.  Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. , 2014, Journal of vascular surgery.

[64]  A. Stanton,et al.  Central Iliac Arteriovenous Anastomosis for Hypertension: Targeting Mechanical Aspects of the Circulation , 2015, Current Hypertension Reports.

[65]  J. Bisognano,et al.  The prevalence, incidence, prognosis, and associated conditions of resistant hypertension. , 2014, Seminars in nephrology.